Abstract
Background By means of echocardiographic assessment and deformation analysis we sought to evaluate the effect of spironolactone versus placebo in addition to standard treatment in patients with paroxysmal or persistent atrial fibrillation (AF) and preserved ejection fraction regarding the performance of the left atrium (LA) and the left ventricle (LV), and quality of life (QOL).
Methods Present double-blind, placebo-controlled study enrolled 125 patients with a history of paroxysmal (n=58) and persistent (n=67) non-valvular AF and LVEF ≥45% that were randomized to spironolactone 25 mg (n=63) or placebo (n=62) once daily in addition to optimal standard treatment. Comprehensive echocardiography and QOL were obtained at inclusion and after 12 months. The primary outcome was 12-month change in LA reservoir function as assessed by peak atrial longitudinal strain (PALS) and peak strain rate (SR-s). Secondary outcomes included LA phasic volumes, global longitudinal strain of left ventricle (GLS), E/e’ ratio, QOL, and recurrent documented episodes of AF.
Results Spironolactone improved the LA reservoir function documented by PALS and SR-s (P =0.03 and P =0.02 for adjusted treatment effect, respectively) but only when adjusting for the parallel changes in blood pressure. Blood pressure significantly reduced in the spironolactone-treated subjects and affected primary outcomes, but not diastolic indices of LV. Transmitral E velocity and E/e’ ratio reduced significantly by spironolactone (P=0.009 for adjusted treatment effect). No differences in secondary outcome parameters were found across treatment groups including volumes, LA geometry, GLS, total number AF recurrences, time-to-first AF recurrence or QOL.
Conclusion Spironolactone improved left atrial reservoir function by lowering blood pressure and decrease E/e’ ratio but did not affect left atrial volumes or geometry, quality of life or recurrent episodes of atrial fibrillation.
Trial registration: ClinicalTrials.org identifier NCT02764619 and EudraCT identifier 2013-000797-30.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02764619
Funding Statement
This study was supported by the Regional Research Board of Southern Denmark in association with Odense University Hospital, Svendborg, the Southern University of Denmark, and the Danish Heart Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Southern Denmark with the trial identifier S-20120220
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- ACEI
- Angiotensin converting enzyme inhibitor
- AF
- Atrial fibrillation
- ARB
- Angiotensin II receptor blocker
- CI
- Confidence interval
- ECG
- 12-lead electrocardiogram
- GLS
- Global longitudinal strain
- LA
- Left atrium
- LV
- Left ventricle / left ventricular
- LVEF
- Left ventricular ejection fraction
- MRA
- Mineralocorticoid receptor antagonist
- PACS
- Peak atrial contraction longitudinal strain
- PALS
- Peak atrial longitudinal strain
- PSL
- Peak systolic longitudinal strain
- PSS
- Peak systolic longitudinal strain rate
- RAAS
- Renin-angiotensin II aldosterone system
- SR-s
- Peak strain rate
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos